Nusinersen, [7] marketed as Spinraza, [4] is a medication used in treating spinal muscular atrophy (SMA), a rare neuromuscular disorder. [8] [4] In December 2016, it became the first approved …

Nusinersen, marketed in the U.S. as Spinraza ® (Biogen) is the first therapy approved for the treatment of SMA. SMA results from mutations in a gene known as SMN1, which encodes a …

SPINRAZA ® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. Increased risk of bleeding complications has been observed …

SPINRAZA (nusinersen) injection, for intrathecal use . Initial U.S. Approval: 2016 _____ INDICATIONS AND USAGE _____ and as clinically needed. SPINRAZA is a survival motor …

One of the latest breakthroughs in care for patients with spinal muscular atrophy is the FDA approval of a new medicine called nusinersen (brand name Spinraza) for the treatment of …

An antisense oligonucleotide (ASO) drug, nusinersen, provides an upcoming and promising treatment option for SMA and represents a novel pharmacological approach with a mechanism …

SPINRAZA ® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. Increased risk of bleeding complications has been observed …

SPINRAZA (nusinersen) injection, for intrathecal use Initial U.S. Approval: 2016 . INDICATIONS AND USAGE . SPINRAZA is a survival motor neuron-2 (SMN2)-directed antisense …

This review article focuses on a novel antisense oligonucleotide treatment, first ever approved for SMA (nusinersen, Spinraza TM) and describes the exciting journey from early ASO clinical …

Jan 23, 2025 · The nusinersen clinical development program encompasses more than 10 clinical studies, which have included more than 460 individuals across a broad spectrum of patient …